Antipsychotic Use and Risk of Breast Cancer in Women With Severe Mental Illness: Replication of a Nationwide Nested Case–Control Database Study

Author:

Solmi Marco12345ORCID,Lähteenvuo Markku6ORCID,Tanskanen Antti678ORCID,Corbeil Olivier910ORCID,Mittendorfer-Rutz Ellenor7ORCID,Correll Christoph U51112ORCID,Tiihonen Jari678ORCID,Taipale Heidi678ORCID

Affiliation:

1. Department of Psychiatry, University of Ottawa , Ontario , Canada

2. SCIENCES LAB, Department of Mental Health, The Ottawa Hospital , Ontario , Canada

3. Ottawa Hospital Research Institute (OHRI), Clinical Epidemiology Program, University of Ottawa , Ontario , Canada

4. School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa , Ontario , Canada

5. Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin , Berlin , Germany

6. Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital , Kuopio , Finland

7. Department of Clinical Neuroscience, Karolinska Institutet , Stockholm , Sweden

8. Center for Psychiatry Research, Stockholm City Council , Stockholm , Sweden

9. Faculty of Pharmacy, Université Laval , Quebec , Canada

10. Department of Pharmacy, Quebec Mental Health University Institute , Quebec , Canada

11. Department of Psychiatry, The Zucker Hillside Hospital , Glen Oaks, NY

12. Department of Psychiatry and Molecular Medicine, Donald and Barbara School of Medicine at Hofstra/Northwell , Hempstead, NY

Abstract

Abstract Background and hypothesis Breast cancer is more prevalent in women with severe mental illness than in the general population, and use of prolactin-increasing antipsychotics may be a contributing factor. Study design A nested case–control study was conducted using the Swedish nationwide registers (inpatient/outpatient care, sickness absence, disability pension, prescribed drugs, cancers). All women aged 18–85 years with schizophrenia/schizoaffective/other nonaffective psychotic disorder/bipolar disorder and breast cancer (cases) were matched for age, primary psychiatric diagnosis, and disease duration with five women without cancer (controls). The association between cumulative exposure to prolactin-increasing/prolactin-sparing antipsychotics and breast cancer was analyzed using conditional logistic regression, adjusted for comorbidities and co-medications. Study results Among 132 061 women, 1642 (1.24%) developed breast cancer between 2010 and 2021, at a mean age of 63.3 ± 11.8 years. Compared with 8173 matched controls, the odds of breast cancer increased in women with prior exposure to prolactin-increasing antipsychotics for 1–4 years (adjusted odds ratio [aOR] = 1.20, 95% confidence interval [CI] = 1.03–1.41), and for ≥ 5 years (aOR = 1.47, 95%CI = 1.26–1.71). There were no increased or decreased odds of breast cancer with exposure to prolactin-sparing antipsychotics of either 1–4 years (aOR = 1.17, 95%CI = 0.98–1.40) or ≥5 years (aOR = 0.99, 95%CI = 0.78–1.26). The results were consistent across all sensitivity analyses (ie, according to different age groups, cancer types, and primary psychiatric diagnosis). Conclusions Although causality remains uncertain, exposure to prolactin-elevating antipsychotics for ≥ 1 year was associated with increased odds of breast cancer in women with severe mental illness. When prescribing antipsychotics, a shared decision-making process should consider individual risk factors for breast cancer.

Funder

Academy of Finland

Swedish Research Council

Publisher

Oxford University Press (OUP)

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Antipsychotic‐associated breast cancer;The Brown University Psychopharmacology Update;2024-09-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3